MarketVIEW: Universal pneumo vaccines

Contents – Executive presentation (MS PowerPoint based)
Author’s note
Executive Summary
Pneumo vaccines: key model model outputs
All pneumo vaccines: available market ($000s) to 2030
All pneumo vaccines: estimated volume (‘000s doses) to 2030
Pneumo vaccines by type: available market ($000s) to 2030
Pneumo vaccines by type: available infant market ($000s) to 2030
Pneumo vaccines by type: all adult market (HI) ($000s) to 2030
Pneumo vaccines: adult market 65yrs+ (HI) ($000s) to 2030
Pneumo vaccines: adult market 18-64yrs (HI) ($000s) to 2030
Pneumo vaccines by type: all adult market (LO) ($000s) to 2030
Pneumo vaccines: adult market 65yrs+ (LO) ($000s) to 2030
Pneumo vaccines: adult market 18-64 yrs (LO) ($000s) to 2030
Pneumo vaccines: available market ($000s) to 2030 by vaccine type
Pneumo vaccines: key model assumptions
Markets covered to 2030
Populations modelled: per age segment
Key model assumptions: product entry and switching
Pricing assumptions applied overall
Pricing assumptions applied per country
Pricing: reimbursement, private/private split
Adult Pneumo indications and vaccination policies
Adult Pneumo indications: definition of risk segments
Adult Pneumo indications: risk groups % of 18-64 yrs cohort
Adult Pneumo indications and vaccination policies: per country
PCV13: adult roll-out assumptions
PUPV: roll-out overall rationale
PUPV: roll-out assumptions per country
Company reported sales analysis
Pneumo vaccines: company reported sales analysis
Company reported sales analysis by vaccine type
Company reported sales analysis by region (cont...)
Epidemiology of pneumococcal disease
Bacterial meningitis per age group (child)/pathogen US 2003-2007*
Bacterial meningitis per age group (adult)/pathogen US 2003-2007
Epidemiology of pneumococcal disease: post vaccine era
Epidemiology of pneumococcal disease: impact of PCV in US
Epidemiology of pneumococcal disease: non PCV7 serotypes (UK)
Epidemiology of pneumococcal disease: non PCV13 serotypes (UK)
Epidemiology of pneumococcal disease: mortality per serotype
Vaccine coverage rates: infants
Vaccine coverage rates: adults
New Pneumo vaccines: brief overview of current R&D
Concept of a protein based pneumo vaccine
PUPV: ideal product profile
GSK2189242A: recombinant-conjugated vaccine
GSK2189242A: Gambia trial
Sanofi Pasteur: multi-protein based PUPV
Sanofi Pasteur: PUPV Bangladesh trial
Current commercial pneumo vaccine pipeline (clinical)
Novel pneumo protein antigens
PATH – new pneumococcal vaccine development
PATH – pneumo vaccine project: overview of collaborators
Bibliography
Disclaimer
About VacZine Analytics
PAGES: ~70 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model(s) (MS Excel-based)
***NOTE*** - there are 2 models (LO & Hi scenarios) each with ~ 90 individual sheets
Title sheet
Important notes
Charts – Val
Charts – Vol
GRAND VALUE SUMMARY
PCV Vol/Val
PPSV Vol/Val
PUPV Vol/Val
0 – 2 yrs per country
US infant
Canada infant
UK infant
Germany infant
France infant
Italy infant
Spain infant
Belgium infant
Netherlands infant
Greece infant
Portugal infant
Poland infant
Other Europe infant
Australia infant
Japan infant
South Korea infant
Other high income infant
Brazil infant
Mexico infant
Turkey infant
Other UMI infant
Other UMI infant (upside)
GAVI active infant
GAVI planned infant
18 – 49 yrs per country
US “at risk”
Canada “at risk”
UK “at risk”
Germany “at risk”
France “at risk”
Italy “at risk”
Spain “at risk”
Belgium “at risk”
Netherlands “at risk”
Greece “at risk”
Portugal “at risk”
Poland “at risk”
Other Europe “at risk”
Australia “at risk”
Japan “at risk”
South Korea “at risk”
Other HI income 18-64 yrs “at risk”
65+ yrs per country
US >65 yrs
Canada >65 yrs
UK >65 yrs
Germany >65 yrs
France >65 yrs
Italy >65 yrs
Spain >65 yrs
Belgium >65 yrs
Netherlands >65 yrs
Greece >65 yrs
Portugal >65 yrs
Poland >65 yrs
Other Europe >65 yrs
Australia >65 yrs
Japan >65 yrs
South Korea >65 yrs
Other HI income >65 yrs
Populations =>
Births
18-64 yrs
65 yrs only
65 yrs +
Sources =>
PPSV price summary
PCV and PUPV price summary
Pub Priv split
At risk groups
Pipeline
Company reported sales